Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 7873 - 7880 of 12086 results
Minor League Baseball Players Strike Out in Attempt to Certify Class for Wage Claims
September 9, 2016| Blog| Viewpoint
2018 Notice of Benefits and Payment: Proposed Updates to the HHS Risk Adjustment Model
September 8, 2016| Blog| Viewpoint
Back to School – Avoiding Theft of Data and Money via the “Business Email Compromise” Scam
September 8, 2016| Blog| Viewpoint
Medicaid Managed Care Transitions' Impact on Brain Injury Waiver Populations
September 8, 2016| News
GAO Report Suggests Discount Coupons Impact Medicare Spending for Part B Drugs
September 7, 2016| Blog| Viewpoint
Welcome Back: New York State Gaming Commission Issues Temporary Permits to Five Daily Fantasy Operators
September 7, 2016| Blog| Viewpoint
First Monday in October Might be Big Day for College Athletes
September 7, 2016| Blog| Viewpoint
The Implications of the Proposed Entrepreneur Rule
September 7, 2016| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|